DBV Technologies - Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 03/31/2024 | 96,434,369 | Total gross of voting rights: 96,434,369 |
| Total net* of voting rights: 96,171,725 |
* Net total = total number of voting rights attached to shares – shares without voting rights
| Last Trade: | US$10.83 |
| Daily Change: | -0.16 -1.46 |
| Daily Volume: | 2,574 |
| Market Cap: | US$296.310M |
January 08, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
